Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.37 |
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21100434 | 0.86 | MGLL (0.33) | — | |
| SCHEMBL17776326 | 0.86 | MGLL (0.33) | — | |
| SCHEMBL871247 | 0.81 | MGLL (0.32) | — | |
| SCHEMBL18751704 | 0.80 | MGLL (0.33) | — | |
| SCHEMBL19658181 | 0.80 | MGLL (0.33) | — | |
| SCHEMBL19658322 | 0.80 | MGLL (0.33) | — | |
| SCHEMBL15326761 | 0.79 | ALDH1A1 (0.35) | MAPTALDH1A1KDM4EGAANPC1 | |
| SCHEMBL2705851 | 0.78 | ALDH1A1 (0.48) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL8914013 | 0.78 | ALDH1A1 (0.48) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL12943060 | 0.78 | ALDH1A1 (0.48) | MAPTCA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077959-A1 | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate | NATIONAL SCIENCE FOUNDATION | 2012-03-29 | — | — | US | disclosed |
| US-20120077959-A1 | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate | NATIONAL SCIENCE FOUNDATION | 2012-03-29 | — | — | US | disclosed |
| WO-2010094029-A2 | ASYMMETRIC CYCLOPROPANATION WITH SUCCINIMIDYL DIAZOACETATE | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010094029-A2 | ASYMMETRIC CYCLOPROPANATION WITH SUCCINIMIDYL DIAZOACETATE | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077959-A1 | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate | SI, STOM, SUCLA2 | MAPT 2345/4885CA1 328/4885CA2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.